Browse drugs

…ad documented clinical response or remission after switching to ustekinumab. 2 patients not responding subsequently switched from ustekinum…

…29 children had significant IBD clinical symptoms when starting Ustekinumab. 16/20 (80%) saw some improvements at 3 months. At 6 months 8/2…

…uding adalimumab, infliximab and vedolizumab, prior to starting Ustekinumab. 12/21 patients stopped treatment because of poor response. 4/1…

…Vedolizumab and Ustekinumab were first approved by our trust for treatment of patients with…

… 20% and 30% of patients, respectively, and 90% achieved higher ustekinumab levels post-intervention.Conclusion and Relevance Although ADA …

… rates and stable clinical disease activity and biomarkers with ustekinumab biosimilars. Biosimilar ustekinumab was well tolerated and appe…

…h anti-IL23-naïve individuals and those previously treated with Ustekinumab, in real-world clinical practice at a tertiary hospital.Materia…

…4 were 51.5% and 45.8% for ustekinumab, and 58.7% and 55.4% for vedolizumab, respectively. In Crohn’s disease, prior infliximab use, male s…

…generalised granuloma annulare (GA) after 3 years of successful ustekinumab therapy for severe palmoplantar psoriasis. Ustekinumab, an inte…

… restricted with only 50.7% of services reporting access.In CD, vedolizumab was accessible in 64/71 services (90.1%), including 31 (43.7%) …

…: p=0,0482; Anti-IL12/23 vs Anti-TNF: p=0,0480; Risankizumab vs Ustekinumab: p=0,0116. No significant differences were found between Risank…

…m diagnosis. 21/23 (91%) received antiTNF prior to switching to Vedolizumab. 2/23(8.7%) had received Ustekinumab. 19/23 (82.6%) were on Aza…